[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
April 4, 2001

Lipid-Lowering Therapy in Acute Coronary Syndromes

Author Affiliations

Author Affiliation: Department of Nutrition, Harvard School of Public Health, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

JAMA. 2001;285(13):1758-1760. doi:10.1001/jama.285.13.1758

In the unstable clinical state after an acute coronary disease event, patients experience a high rate of serious complications including death, myocardial infarction (MI), and progressively recurring unstable angina requiring intervention.1 The incidence rate sharply declines after 1 month, and then gradually diminishes so that after about 6 months, the incidence of coronary death and MI is fairly constant for the next several years, reflecting a stabilization of the clinical coronary disease. Many successful clinical strategies—including antithrombotic therapy, β-adrenergic blockade, thrombolysis, and angiotensin-converting enzyme inhibition—have been directed toward reducing the high early event rate after onset of acute coronary syndrome.1 Nonetheless, the incidence of serious complications remains high.

First Page Preview View Large
First page PDF preview
First page PDF preview
×